Convalescent plasma, an experimental COVID-19 treatment under Investigational New Drug (IND) exemption from the FDA, is gaining popularity throughout the United States and around the world.

This therapy collects blood plasma from recovered COVID-19 patients for injection in those sick with the virus. Like all blood products, this plasma must pass the FDA’s stringent donation guidelines and testing regimen before it can be used in a patient.

Supporting Convalescent Plasma

Drucker Diagnostics is proud to support the hospitals and plasma centers working with convalescent plasma. Blood typing is a vital part of the preparation process for both the donor and the patient. Designed for easy blood typing, the Drucker SERO 12 blood banking centrifuge helps simplify convalescent plasma workflow.

To minimize disruption during this hectic time, the SERO 12 uses the same rotor as the Sero-Fuge™ so existing serology processes can remain unchanged. The SERO 12 offers all the best features of the Sero-Fuge™ with a few key upgrades. Programming for your lab’s needs simple and fast with the digital display and user-friendly interface. Set time in 5 or 15 second increments, and save up to 10 fully custom cycles to easily validate and spin.

Designed, built, and supported in the USA, the SERO-12 is ready to ship today with no delays to support the urgent convalescent plasma need.